Plain-English translation of NCT07638436 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new immunotherapy drug called adebrelimab combined with two chemotherapy medications (paclitaxel and carboplatin) for patients with esophageal squamous cell carcinoma that is borderline resectable — meaning surgery might be possible but is uncertain. The goal is to see if adding this medication to chemotherapy can shrink the tumors enough to make surgery feasible, or to help control the cancer if surgery isn't possible.
Many patients with esophageal cancer have tumors that are in a gray zone — too advanced to safely operate on right away, but not so advanced that surgery is impossible. Doctors want to know if this medication can improve outcomes by making more tumors operable or by better controlling the disease.
You likely qualify if…
You likely don't qualify if…
You will receive the medication and chemotherapy in 3-week treatment cycles. After 2 cycles, doctors will scan your tumor to see if it has shrunk enough to allow surgery; if so, you'll have surgery. If the tumor hasn't shrunk enough, you may receive a third cycle of treatment followed by another scan. Depending on how your cancer responds, you may then proceed to surgery, radiation therapy combined with chemotherapy, or other advanced cancer treatments. The trial involves regular doctor visits, imaging scans, and blood tests to monitor your health and how well the treatment is working.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China